Danmarks Tekniske Universitet

Nanovi Radiotherapy Aps

Enkam Pharmaceuticals A/s

Medicometrics Aps

Morten Albrechtsen

Thomas Lars Andresen

Rasmus Irming Jolck

Elisabeth Bock

Vladimir Berezin

Rasmus Irming Jølck

Arne Holm

Ole Olsen

Lise Norkjaer Bjerg

Niels Harrit

Lise Nørkjaer Bjerg

Lars Noergaard

Rasmus Bro-Joergensen

Rasmus Irming JØLCK

The present invention describes an X-ray contrast composition for local administration, wherein the X-ray contrast composition exhibits contrast properties and wherein at least 60% of an administrated amount of said X-ray contrast composition remains more than 24 hours within 10 cm from an injection point when the X-ray contrast composition is administrated to a human or animal body.

Gel formulations for guiding radiotherapy

The present invention relates to novel formulations comprising a plurality of nano-sized solid particles and a gel-forming system, useful, e.g. for imaging of the body of a mammal. Also described are kits comprising such formulations and imaging methods utilizing such formulations or kits.

Formulation of solid nano-sized particles in a gel-forming system

The present invention relates to a method for modulating the interaction between at least two proteins, wherein at least one of the two proteins is a functional cell-surface receptor and the other protein is the receptor ligand. The invention features a binding site of said functional cell-surface receptor on the receptor ligand and discloses a series of amino acid sequences, which are part of the structure of said binding site and/or involved in the interaction between the receptor and the ligand. Moreover, the present invention features methods for molecular design and screening of a candidate compound capable of modulating the interaction between the functional cell-surface receptor and receptor ligand through the described binding site, and provides a screening assay for identification of such a compound. The invention further describes an antibody capable of binding to the above binding site and/or to an epitope comprising an amino acid sequence essential for executing the receptor ligand interaction through said binding site. The invention also concerns a variety of uses of the disclosed methods, peptide sequences and antibodies. The invention in preferred embodiments concerns the binding site of the fibroblast growth factor receptor (FGFR) on FGFR ligands, compounds capable of modulating the receptor ligand interaction through said binding site, and antibody capable of recognition of said binding site.

Compounds capable of interacting with a cell-surface fibroblast growth factor receptor

The present invention relates to a method of training a classification system for characterising a biological sample, a diagnostic classification system, as well as a method of characterising a condition in an animal or a human being by using parameters obtained from the sample. The invention relates to classification based on physical parameters obtained from luminescence spectroscopy on light emitted from the sample. The data obtained from a spectrofluorimetric analysis can be considered a finger-print of the sample. Each sample gives rise to a unique spectrofluorometric set of physical parameters. By analysing the fluorescence data, it is possible to classify samples into two or more classes based on the fluorescence spectra, such as classifying with respect to presence/abs of a specific disease, group of diseases or risk of later attaining a specific disease or a body condition, or concentration of a specific compound or medicine.

Method and system for classifying a biological sample

Growing community of inventors

Charlottenlund, Denmark

Morten Albrechtsen